Compare RNA & IAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNA | IAG |
|---|---|---|
| Founded | 2012 | 1990 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.5M | 11.2B |
| IPO Year | 2025 | 2002 |
| Metric | RNA | IAG |
|---|---|---|
| Price | $14.04 | $18.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 4 |
| Target Price | ★ $69.26 | $17.75 |
| AVG Volume (30 Days) | 394.0K | ★ 6.2M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $88.12 | $44.84 |
| Revenue Next Year | $18.11 | $1.33 |
| P/E Ratio | ★ N/A | $18.66 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.95 | $6.34 |
| 52 Week High | $73.06 | $24.87 |
| Indicator | RNA | IAG |
|---|---|---|
| Relative Strength Index (RSI) | 26.62 | 46.08 |
| Support Level | $13.06 | $17.20 |
| Resistance Level | $72.75 | $22.47 |
| Average True Range (ATR) | 0.59 | 0.88 |
| MACD | 1.67 | 0.18 |
| Stochastic Oscillator | 71.57 | 50.88 |
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Iamgold Corp is a mid-tier gold mining company. The company operating gold mines are divided into geographic segments such as Cote Gold mine - Canada, Burkina Faso - Essakane mine, Westwood mine - Canada. The company's s non-gold mine segments are Exploration and evaluation and development, and Corporate - which includes royalty interests. The company generates the majority of its revenue from the Cote Gold mine segment.